» Articles » PMID: 38103838

Low-dose Buprenorphine Initiation and Treatment Continuation Among Hospitalized Patients with Opioid Dependence: A Retrospective Cohort Study

Overview
Specialty Psychiatry
Date 2023 Dec 16
PMID 38103838
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Buprenorphine is an effective treatment for both opioid use disorder (OUD) and chronic pain, but buprenorphine's pharmacology complicates treatment initiation for some patients. Low-dose buprenorphine initiation is a novel strategy that may reduce precipitated withdrawal. Few studies describe what patient populations benefit most from low-dose initiations and the clinical parameters that impact treatment continuation. This study aimed to 1) describe experiences with low-dose buprenorphine initiation, including both successes and failures among hospitalized patients in an urban underserved community; 2) identify patient- and treatment-related characteristics associated with unsuccessful initiation and treatment discontinuation; and 3) assess buprenorphine treatment continuation after discharge.

Methods: This is a retrospective cohort study with opioid-dependent (meaning OUD or receiving long-term opioid therapy for chronic pain) patients who underwent low-dose buprenorphine initiation during hospital admission from October 2021 through April 2022. The primary outcome was successful completion of low-dose initiation. Bivariate analysis identified patient- and treatment-related factors associated with unsuccessful initiation. Secondary outcomes were buprenorphine treatment discontinuation at post-discharge follow-up, 30- and 90-days.

Results: Of 28 patients who underwent low-dose buprenorphine initiation, 68 % successfully completed initiation. Unsuccessful initiation was associated with receipt of methadone during admission and higher morphine milligram equivalents (MME) of supplemental opioids. Of 22 patients with OUD, the percent receiving a buprenorphine prescription at a follow-up visit, 30 days, and 90 days, respectively, was 46 %, 36 %, and 36 %. Of 6 patients with chronic pain, the percent receiving a buprenorphine prescription at a follow-up visit, 30 days, and 90 days, respectively, was 100 %, 100 %, and 83 %.

Conclusion: Low-dose buprenorphine initiation can be successful in opioid-dependent hospitalized patients. Patients taking methadone or requiring higher MME of supplemental opioids may have more difficulty with the low-dose buprenorphine initiation approach, but these findings should be replicated in larger studies. This study suggests patient- and treatment-related factors that clinicians could consider when determining the optimal treatment strategy for patients wishing to transition to buprenorphine.

Citing Articles

Opioid conversion in adults with cancer: MASCC-ASCO-AAHPM-HPNA-NICSO guideline.

Davis M, Davies A, McPherson M, Reddy A, Paice J, Roeland E Support Care Cancer. 2025; 33(3):243.

PMID: 40029420 DOI: 10.1007/s00520-025-09286-z.


Outpatient Low-Dose Initiation of Buprenorphine for People Using Fentanyl.

Suen L, Chiang A, Jones B, Soran C, Geier M, Snyder H JAMA Netw Open. 2025; 8(1):e2456253.

PMID: 39853975 PMC: 11762237. DOI: 10.1001/jamanetworkopen.2024.56253.


Low-Dose Buprenorphine Initiation for Hospitalized Patients With Chronic Pain and Opioid Use Disorder or Opioid Misuse: Protocol for an Open-Label, Parallel-Group, Effectiveness-Implementation Randomized Controlled Trial.

Hayes B, Sanchez Fat G, Torres-Lockhart K, Khalid L, Minami H, Ghiroli M Subst Use Addctn J. 2024; 46(1):184-191.

PMID: 39068540 PMC: 11652261. DOI: 10.1177/29767342241263221.

References
1.
Jakubowski A, Lu T, DiRenno F, Jadow B, Giovanniello A, Nahvi S . Same-day vs. delayed buprenorphine prescribing and patient retention in an office-based buprenorphine treatment program. J Subst Abuse Treat. 2020; 119:108140. PMC: 7609975. DOI: 10.1016/j.jsat.2020.108140. View

2.
Lintzeris N, Mankabady B, Rojas-Fernandez C, Amick H . Strategies for Transfer From Methadone to Buprenorphine for Treatment of Opioid Use Disorders and Associated Outcomes: A Systematic Review. J Addict Med. 2021; 16(2):143-151. PMC: 8920020. DOI: 10.1097/ADM.0000000000000855. View

3.
Eklund C, Hiltunen A, Melin L, Borg S . Abstinence fear in methadone maintenance withdrawal: a possible obstacle for getting off methadone. Subst Use Misuse. 1997; 32(6):779-92. DOI: 10.3109/10826089709039377. View

4.
Cunningham J, Sobell L, Sobell M, Agrawal S, Toneatto T . Barriers to treatment: why alcohol and drug abusers delay or never seek treatment. Addict Behav. 1993; 18(3):347-53. DOI: 10.1016/0306-4603(93)90036-9. View

5.
Wong J, Nikoo M, Westenberg J, Suen J, Wong J, Krausz R . Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Addict Sci Clin Pract. 2021; 16(1):11. PMC: 7881636. DOI: 10.1186/s13722-021-00220-2. View